Buxbaum completed a Postdoctoral Fellowship in Molecular and Cellular Neuroscience at the Rockefeller University (New York, NY) in 1991 in Paul Greengard's group.
[3] Buxbaum's research focuses on using genetic and functional methods to identify and characterize genes and pathways involved in autism, schizophrenia, and Alzheimer disease.
His group has an extensive functional genomics laboratory using yeast two hybrid, cultured cells, and rodent and other animal models in neuropsychiatric disorders.
Functional studies in his laboratory have led to pathway discovery in autism, schizophrenia and Alzheimer disease, to more than a dozen animal models,[27][28][29] and to a clinical trial showing preliminary efficacy in patients with a SHANK3 mutation.
He has been recognized by the NYU Child Study Center (2004), the UC Davis/MIND Institute (2011), and the Autism Spectrum News (2014 Leadership Award[33]) for his work on the causes and treatment of ASD.